Overview

A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Recurrent/Metastatic Head and Neck Cancers

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

This is a multicenter, open-label, single-arm, phase Ib study to evaluate the safety and efficacy of Mitoxantrone Hydrochloride Liposome in subjects with recurrent/metastatic Head and Neck Cancers

Phase:

Phase 1

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Treatments:

Mitoxantrone